HealthEquity Reports Second Quarter Ended July 31, 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Jefferies Reiterates Buy Rating on HealthEquity, Inc (HQY) Following Beat and Raise
September 7, 2022 8:22 AM EDTJefferies analyst Glen Santangelo reiterated a Buy rating and $80.00 price target on HealthEquity, Inc (NASDAQ: HQY) following Q2 beat and raise.
The analyst commented, "2Q beat & raise was driven by ongoing momentum in HSA acct/asset growth and higher HSA yield -owing... More
HealthEquity (HQY) Reports In-Line Q2 EPS
September 6, 2022 4:02 PM EDTHealthEquity (NASDAQ: HQY) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $206.1 million versus the consensus estimate of $203.82 million.
GUIDANCE:
HealthEquity sees FY2022 EPS of $1.23-$1.32, versus the consensus of $1.28. HealthEquity sees... More
